Literature DB >> 22995655

Is the mitochondrial outermembrane protein VDAC1 therapeutic target for Alzheimer's disease?

P Hemachandra Reddy1.   

Abstract

Mitochondrial dysfunction and synaptic damage have been described as early events in Alzheimer's disease (AD) pathogenesis. Recent research using AD postmortem brains, and AD mouse and cell models revealed that amyloid beta (Aβ) and tau hyperphosphorylation are involved in mitochondrial dysfunction and synaptic damage in AD. Further, recent research also revealed that the protein levels of mitochondrial outer membrane protein, voltage-dependent anion channel 1 (VDAC1), are elevated in the affected regions of AD postmortem brains and cortical tissues from APP transgenic mice. In addition, emerging research using AD postmortem brains and AD mouse models revealed that VDAC1 is linked to Aβ and phosphorylated tau, blocks the mitochondrial permeability transition (MPT) pores, disrupts the transport of mitochondrial proteins and metabolites, impairs gating of VDAC, and causes defects in oxidative phosphorylation, leading to mitochondrial dysfunction in AD neurons. The purpose of this article is to review research that has investigated the relationship between VDAC1 and the regulation of MPT pores in AD progression.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22995655      PMCID: PMC3518645          DOI: 10.1016/j.bbadis.2012.09.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  97 in total

1.  Molecular clock and gene function.

Authors:  Cecilia Saccone; Corrado Caggese; Anna Maria D'Erchia; Cecilia Lanave; Marta Oliva; Graziano Pesole
Journal:  J Mol Evol       Date:  2003       Impact factor: 2.395

2.  Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease.

Authors:  P Hemachandra Reddy; M Flint Beal
Journal:  Trends Mol Med       Date:  2008-01-22       Impact factor: 11.951

3.  Mitochondria morphology and DNA content upon sublethal exposure to beta-amyloid(1-42) peptide.

Authors:  Andrea Diana; Goran Simić; Elena Sinforiani; Nicola Orrù; Giuseppina Pichiri; Giorgio Bono
Journal:  Coll Antropol       Date:  2008-01

4.  Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease.

Authors:  Heng Du; Lan Guo; Fang Fang; Doris Chen; Alexander A Sosunov; Guy M McKhann; Yilin Yan; Chunyu Wang; Hong Zhang; Jeffery D Molkentin; Frank J Gunn-Moore; Jean Paul Vonsattel; Ottavio Arancio; John Xi Chen; Shi Du Yan
Journal:  Nat Med       Date:  2008-09-21       Impact factor: 53.440

5.  The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae.

Authors:  Camilla A Hansson Petersen; Nyosha Alikhani; Homira Behbahani; Birgitta Wiehager; Pavel F Pavlov; Irina Alafuzoff; Ville Leinonen; Akira Ito; Bengt Winblad; Elzbieta Glaser; Maria Ankarcrona
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-29       Impact factor: 11.205

6.  Protein kinase Cepsilon interacts with and inhibits the permeability transition pore in cardiac mitochondria.

Authors:  Christopher P Baines; Chang-Xu Song; Yu-Ting Zheng; Guang-Wu Wang; Jun Zhang; Ou-Li Wang; Yiru Guo; Roberto Bolli; Ernest M Cardwell; Peipei Ping
Journal:  Circ Res       Date:  2003-03-27       Impact factor: 17.367

7.  VDAC2 inhibits BAK activation and mitochondrial apoptosis.

Authors:  Emily H Y Cheng; Tatiana V Sheiko; Jill K Fisher; William J Craigen; Stanley J Korsmeyer
Journal:  Science       Date:  2003-07-25       Impact factor: 47.728

Review 8.  Genetic strategies for dissecting mammalian and Drosophila voltage-dependent anion channel functions.

Authors:  William J Craigen; Brett H Graham
Journal:  J Bioenerg Biomembr       Date:  2008-06       Impact factor: 2.945

9.  Soluble beta-amyloid leads to mitochondrial defects in amyloid precursor protein and tau transgenic mice.

Authors:  Anne Eckert; Susanne Hauptmann; Isabel Scherping; Virginie Rhein; Franz Müller-Spahn; Jürgen Götz; Walter E Müller
Journal:  Neurodegener Dis       Date:  2008-03-06       Impact factor: 2.977

10.  Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells.

Authors:  Hindupur K Anandatheerthavarada; Gopa Biswas; Marie-Anne Robin; Narayan G Avadhani
Journal:  J Cell Biol       Date:  2003-04-14       Impact factor: 10.539

View more
  34 in total

1.  Mitochondrial Proteome Changes Correlating with β-Amyloid Accumulation.

Authors:  Katalin Völgyi; Krisztina Háden; Viktor Kis; Péter Gulyássy; Kata Badics; Balázs András Györffy; Attila Simor; Zoltán Szabó; Tamás Janáky; László Drahos; Árpád Dobolyi; Botond Penke; Gábor Juhász; Katalin Adrienna Kékesi
Journal:  Mol Neurobiol       Date:  2016-02-24       Impact factor: 5.590

2.  Differential proteomic and behavioral effects of long-term voluntary exercise in wild-type and APP-overexpressing transgenics.

Authors:  Shailaja Kishan Rao; Jordan M Ross; Fiona E Harrison; Alexandra Bernardo; Randall S Reiserer; Ronald S Reiserer; James A Mobley; Michael P McDonald
Journal:  Neurobiol Dis       Date:  2015-03-25       Impact factor: 5.996

Review 3.  Revisiting trends on mitochondrial mega-channels for the import of proteins and nucleic acids.

Authors:  María Luisa Campo; Pablo M Peixoto; Sonia Martínez-Caballero
Journal:  J Bioenerg Biomembr       Date:  2016-05-05       Impact factor: 2.945

Review 4.  A Mitocentric View of Alzheimer's Disease.

Authors:  Hao Hu; Chen-Chen Tan; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2016-10-01       Impact factor: 5.590

5.  Modulation of human mitochondrial voltage-dependent anion channel 2 (hVDAC-2) structural stability by cysteine-assisted barrel-lipid interactions.

Authors:  Svetlana Rajkumar Maurya; Radhakrishnan Mahalakshmi
Journal:  J Biol Chem       Date:  2013-07-19       Impact factor: 5.157

Review 6.  Are circulating microRNAs peripheral biomarkers for Alzheimer's disease?

Authors:  Subodh Kumar; P Hemachandra Reddy
Journal:  Biochim Biophys Acta       Date:  2016-06-02

Review 7.  Molecular Targets of Cannabidiol in Neurological Disorders.

Authors:  Clementino Ibeas Bih; Tong Chen; Alistair V W Nunn; Michaël Bazelot; Mark Dallas; Benjamin J Whalley
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

8.  Reduced VDAC1 protects against Alzheimer's disease, mitochondria, and synaptic deficiencies.

Authors:  Maria Manczak; Tatiana Sheiko; William J Craigen; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

9.  The osteogenic effect of liraglutide involves enhanced mitochondrial biogenesis in osteoblasts.

Authors:  Subhashis Pal; Shailendra K Maurya; Sourav Chattopadhyay; Shyamsundar Pal China; Konica Porwal; Chirag Kulkarni; Sabyasachi Sanyal; Rohit A Sinha; Naibedya Chattopadhyay
Journal:  Biochem Pharmacol       Date:  2019-03-15       Impact factor: 5.858

Review 10.  Role of cysteines in mammalian VDAC isoforms' function.

Authors:  Vito De Pinto; Simona Reina; Ankit Gupta; Angela Messina; Radhakrishnan Mahalakshmi
Journal:  Biochim Biophys Acta       Date:  2016-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.